Search the Newsreel

Gyre Therapeutics appoints three directors to board By Investing.com

Gyre Therapeutics has announced the appointment of three new directors to its Board, effective August 1, 2026. These appointments follow the company's acquisition of Cullgen Inc. and the acceptance of its New Drug Application for F351 by China's NMPA. Despite these developments, InvestingPro suggests …

Gyre Therapeutics (GYRE) Registration filing Summary

Gyre Therapeutics (GYRE) filed a registration summary detailing its business as a commercial-stage biopharmaceutical company focusing on small-molecule therapies for organ fibrosis and inflammatory diseases, with operations spanning the U.S. and China. The company recently merged with Cullgen, expanding into targeted protein degrader technology …

Gyre Therapeutics Appoints Three New Members to its Board of Directors

Gyre Therapeutics announced the appointment of three new members to its Board of Directors: Dr. Yue Xiong, Maxwell Kirkby, and Dr. Claire Weston, effective August 1, 2026. These appointments aim to enhance the Board's expertise in scientific, clinical development, and cross-border biopharmaceutical operations as …

Gyre Therapeutics appoints three directors to board

Gyre Therapeutics announced the appointment of three new directors to its Board, effective August 1, 2026: Dr. Yue Xiong as Chief Scientific Officer, Maxwell Kirkby, and Dr. Claire Weston. This follows recent significant activities for the company, including the acquisition of Cullgen Inc. and …

Gyre Therapeutics (Nasdaq: GYRE) adds three directors, expanding expertise

Gyre Therapeutics announced the appointment of three new directors to its board, effective August 1, 2026: Dr. Yue Xiong, Maxwell Kirkby, and Dr. Claire Weston. These additions aim to expand the company's expertise in scientific, clinical development, and cross-border biopharmaceutical operations. Kirkby and Weston …

Gyre Adds Director With Drug Development Experience Across China, Japan

Gyre Therapeutics has appointed three new directors to its Board, effective August 1, 2026: Yue Xiong, Maxwell Kirkby, and Claire Weston. These appointments aim to bolster the company's scientific, clinical development, governance, and cross-border biopharmaceutical expertise as it advances its pipeline. The new directors …

Gyre Therapeutics Inc. (GYRE) Q1 2026 Earnings: Narrower Net Loss Beats Estimates as Operational Discipline Progresses - Net Income Trends

Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates

Gyre Therapeutics to acquire Cullgen in $300M all-stock transaction

Gyre Therapeutics (GYRE) Stock Price, News & Analysis

Should I buy Gyre Therapeutics, Inc. (GYRE)